Why is fair value unavailable for Bolt Biotherapeutics (NASDAQ-BOLT) stock?

A reliable fair value estimate is not currently available for Bolt Biotherapeutics (NASDAQ-BOLT). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

How is the financial health of Bolt Biotherapeutics?

The current financial health read for Bolt Biotherapeutics (NASDAQ-BOLT) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

Does Bolt Biotherapeutics (NASDAQ-BOLT) pay dividends?

The latest available data indicates no current dividend yield for Bolt Biotherapeutics (NASDAQ-BOLT).

What is the market capitalization of Bolt Biotherapeutics?

The current market capitalization listed for Bolt Biotherapeutics is 16.496 M.

What is the ticker symbol for Bolt Biotherapeutics?

The ticker symbol for Bolt Biotherapeutics is NASDAQ-BOLT, and the stock is listed on NASDAQ.

Where is Bolt Biotherapeutics (NASDAQ-BOLT) listed?

Bolt Biotherapeutics (NASDAQ-BOLT) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Bolt Biotherapeutics?

The current debt-to-total-capital ratio listed for Bolt Biotherapeutics is 63.9%, which helps investors evaluate the company’s financing structure and leverage profile.

Bolt Biotherapeutics (BOLT) Fair Value & Stock Analysis

Bolt Biotherapeutics (BOLT)

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker BOLT. The company focuses on developing immunotherapy candidates for cancer, with programs aimed at a range of solid tumors. Its pipeline includes BDC-4182, designed to target claudin 18.2 in cancers such as gastric and gastroesophageal junction cancer and pancreatic cancer; BDC-3042, which is being developed for indications including non-small cell lung cancer and melanoma; CEA ISAC, aimed at tumors that express carcinoembryonic antigen cell adhesion molecule 5; and PD-L1 ISAC, an antibody conjugate intended to engage tumor and immune cells. Bolt Biotherapeutics also has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, along with a license agreement with Stanford University. The company was founded in 2015 and is based in Redwood City, California.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Analyst Price Target	Analyst Target Upside/Downside	Overall Financial Health	Dividend Yield	Market Cap	Total Debt / Total Capital	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-BOLT	Not available	Not available	Not available	Fair	0.0%	16.496 M	63.9%	-18.1	109.7%